Dextrostat Related Published Studies
Well-designed clinical trials related to Dextrostat (Dextroamphetamine)
A randomized, placebo-controlled trial of sustained-release dextroamphetamine for treatment of methamphetamine addiction. [2011.02]
Minocycline attenuates subjective rewarding effects of dextroamphetamine in humans. [2011.01]
A randomized, placebo-controlled trial of sustained-release dextroamphetamine for
treatment of methamphetamine addiction. [2011]
Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder. [2009.11]
Sustaining executive functions during sleep deprivation: A comparison of caffeine, dextroamphetamine, and modafinil. [2009.02.01]
Sustaining executive functions during sleep deprivation: A comparison of caffeine, dextroamphetamine, and modafinil. [2009.02]
Atomoxetine attenuates dextroamphetamine effects in humans. [2009]
Restoration of risk-propensity during sleep deprivation: caffeine, dextroamphetamine, and modafinil. [2008.09]
Effects of dextroamphetamine, caffeine and modafinil on psychomotor vigilance test performance after 44 h of continuous wakefulness. [2008.09]
Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge. [2008.06]
Relative bioavailability of scopolamine dosage forms and interaction with dextroamphetamine. [2007.07]
A randomized double-blind trial of paroxetine and/or dextroamphetamine and problem-focused therapy for attention-deficit/hyperactivity disorder in adults. [2006.04]
Physiotherapy coupled with dextroamphetamine for rehabilitation after hemiparetic stroke: a randomized, double-blind, placebo-controlled trial. [2006.01]
Valproate attenuates dextroamphetamine-induced subjective changes more than lithium. [2005.12]
Lithium and valproate attenuate dextroamphetamine-induced changes in brain activation. [2005.03]
Dextroamphetamine pilot crossover trials and n of 1 trials in patients with chronic tension-type and migraine headache. [2004.11]
Probing brain reward system function in major depressive disorder: altered response to dextroamphetamine. [2002.05]
Steady-state pharmacokinetics and tolerability of modafinil administered alone or in combination with dextroamphetamine in healthy volunteers. [2002.04]
Dextroamphetamine for cocaine-dependence treatment: a double-blind randomized clinical trial. [2001.10]
Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder. [2001.04]
Placebo-controlled evaluation of amphetamine mixture-dextroamphetamine salts and amphetamine salts (Adderall): efficacy rate and side effects. [2001.01]
Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial. [2000.06]
Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults. [2000.01]
Comparison of the single-dose pharmacokinetics and tolerability of modafinil and dextroamphetamine administered alone or in combination in healthy male volunteers. [1998.10]
Diltiazem, a calcium antagonist, partly attenuates the effects of dextroamphetamine in healthy volunteers. [1997.03]
Minimal effects of dextroamphetamine on scopolamine-induced cognitive impairments in humans. [1997.01.01]
Comparison of methods for the assessment of central nervous system stimulant response after dextroamphetamine administration to healthy male volunteers. [1996.11]
Dextroamphetamine enhances "neural network-specific" physiological signals: a positron-emission tomography rCBF study. [1996.08.01]
Comparative abuse liability of sertraline, alprazolam, and dextroamphetamine in humans. [1995.04]
Interaction between ethanol and dextroamphetamine: effects on psychomotor performance. [1992.02]
Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia. [1991.01]
Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: a comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline. [1990.08]
Fenfluramine and dextroamphetamine treatment of childhood hyperactivity. Clinical and biochemical findings. [1989.03]
Well-designed clinical trials possibly related to Dextrostat (Dextroamphetamine)
Aggregated n-of-1 trials of central nervous system stimulants versus placebo for
paediatric traumatic brain injury--a pilot study. [2014]
Health-related quality of life and functional outcomes from a
randomized-withdrawal study of long-term lisdexamfetamine dimesylate treatment in
children and adolescents with attention-deficit/hyperactivity disorder. [2014]
A post hoc comparison of the effects of lisdexamfetamine dimesylate and
osmotic-release oral system methylphenidate on symptoms of attention-deficit
hyperactivity disorder in children and adolescents. [2013]
Central nervous system stimulants for secondary attention deficit-hyperactivity
disorder after paediatric traumatic brain injury: a rationale and protocol for
single patient (n-of-1) multiple cross-over trials. [2013]
Lisdexamfetamine dimesylate improves processing speed and memory in cognitively
impaired MS patients: a phase II study. [2013]
A randomized controlled trial of CBT therapy for adults with ADHD with and
without medication. [2012]
Dose response effects of lisdexamfetamine dimesylate treatment in adults with
ADHD: an exploratory study. [2012]
Effect of lisdexamfetamine dimesylate on sleep in children with ADHD. [2011.08]
Impact of stimulant pharmacotherapy on sleep quality: post hoc analyses of 2 large, double-blind, randomized, placebo-controlled trials. [2011.07]
Long-term treatment outcomes with lisdexamfetamine dimesylate for adults with attention-deficit/hyperactivity disorder stratified by baseline severity. [2011.06]
Functional magnetic resonance imaging investigation of the amphetamine sensitization model of schizophrenia in healthy male volunteers. [2011.06]
Comparison of the behavioral and cardiovascular effects of intranasal and oral d-amphetamine in healthy human subjects. [2011.06]
Effects of open-label lisdexamfetamine dimesylate on self-reported quality of life in adults with ADHD. [2011.05]
Various anti-motion sickness drugs and core body temperature changes. [2011.04]
Effect size of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. [2011.03]
Zinc for attention-deficit/hyperactivity disorder: placebo-controlled double-blind pilot trial alone and combined with amphetamine. [2011.02]
Intranasal versus oral administration of lisdexamfetamine dimesylate: a randomized, open-label, two-period, crossover, single-dose, single-centre pharmacokinetic study in healthy adult men. [2011]
Pharmacological treatment for Attention Deficit Hyperactivity Disorder (ADHD) in
children with comorbid tic disorders. [2011]
Prediction of placebo response in 2 clinical trials of lisdexamfetamine
dimesylate for the treatment of ADHD. [2011]
Effect of lisdexamfetamine dimesylate on sleep in children with ADHD. [2011]
Serum ferritin and amphetamine response in youth with attention-deficit/hyperactivity disorder. [2010.12]
Sustained release d-amphetamine reduces cocaine but not 'speedball'-seeking in buprenorphine-maintained volunteers: a test of dual-agonist pharmacotherapy for cocaine/heroin polydrug abusers. [2010.12]
Open-label administration of lisdexamfetamine dimesylate improves executive function impairments and symptoms of attention-deficit/hyperactivity disorder in adults. [2010.09]
Effect of D-amphetamine on inhibition and motor planning as a function of baseline performance. [2010.09]
Duration of effect of oral long-acting stimulant medications for ADHD throughout the day. [2010.08]
Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users. [2010.07]
Verbal memory improved by D-amphetamine: influence of the testing effect. [2010.07]
Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design. [2010.06.24]
Stress-induced changes in mood and cortisol release predict mood effects of amphetamine. [2010.06.01]
Use of an acute challenge with d-amphetamine to model cognitive improvement in chronic schizophrenia. [2010.06]
Cocaine choice in humans during D-amphetamine maintenance. [2010.04]
Polymorphisms in dopamine transporter (SLC6A3) are associated with stimulant effects of D-amphetamine: an exploratory pharmacogenetic study using healthy volunteers. [2010.03]
Efficacy of psychostimulant drugs for cocaine dependence. [2010.02.17]
Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, crossover study. [2010.02]
Are attention lapses related to d-amphetamine liking? [2010.02]
Randomized controlled trial of dexamphetamine maintenance for the treatment of methamphetamine dependence. [2010.01]
Improvements in executive function correlate with enhanced performance and
functioning and health-related quality of life: evidence from 2 large,
double-blind, randomized, placebo-controlled trials in ADHD. [2010]
Randomized, double-blind, placebo-controlled, crossover study of the efficacy and
safety of lisdexamfetamine dimesylate in adults with
attention-deficit/hyperactivity disorder: novel findings using a simulated adult
workplace environment design. [2010]
Use of an acute challenge with d-amphetamine to model cognitive improvement in
chronic schizophrenia. [2010]
Effectiveness of medications used to attenuate antipsychotic-related weight gain
and metabolic abnormalities: a systematic review and meta-analysis. [2010]
Effects of lisdexamfetamine dimesylate treatment for ADHD on growth. [2010]
Short-term effects of lisdexamfetamine dimesylate on cardiovascular parameters in a 4-week clinical trial in adults with attention-deficit/hyperactivity disorder. [2009.12]
Evaluation of genetic variability in the dopamine receptor D2 in relation to behavioral inhibition and impulsivity/sensation seeking: an exploratory study with d-amphetamine in healthy participants. [2009.12]
Adjunctive divalproex versus placebo for children with ADHD and aggression refractory to stimulant monotherapy. [2009.12]
Further evidence of association between amphetamine response and SLC6A2 gene variants. [2009.10]
Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. [2009.09]
Modafinil as a potential motion sickness countermeasure. [2009.08]
Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. [2009.06]
Amphetamine-induced place preference in humans. [2009.05.15]
A randomized, double-blind, placebo-controlled trial assessing the impact of dexamphetamine on fatigue in patients with advanced cancer. [2009.04]
The effects of d-amphetamine on extrastriatal dopamine D2/D3 receptors: a randomized, double-blind, placebo-controlled PET study with [11C]FLB 457 in healthy subjects. [2009.03]
Cocaine effects during D-amphetamine maintenance: a human laboratory analysis of safety, tolerability and efficacy. [2009.01.01]
Effect of lisdexamfetamine dimesylate on parent-rated measures in children aged 6 to 12 years with attention-deficit/hyperactivity disorder: a secondary analysis. [2008.09]
Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. [2008.09]
Infrequent illicit methadone use among stimulant-using patients in methadone maintenance treatment programs: a national drug abuse treatment clinical trials network study. [2008.07]
Naltrexone attenuates the subjective effects of amphetamine in patients with amphetamine dependence. [2008.07]
Relative bioavailability of lisdexamfetamine 70-mg capsules in fasted and fed healthy adult volunteers and in solution: a single-dose, crossover pharmacokinetic study. [2008.03]
The explicit learning of new names for known objects is improved by dexamphetamine. [2008.03]
Daytime Ayahuasca administration modulates REM and slow-wave sleep in healthy volunteers. [2008.02]
Riluzole and D-amphetamine interactions in humans. [2008.01.01]
Dexamphetamine enhances explicit new word learning for novel objects. [2007.12]
Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. [2007.11.01]
Dexamphetamine boosts naming treatment effects in chronic aphasia. [2007.11]
Long-term changes in management following n-of-1 trials of stimulants in attention-deficit/hyperactivity disorder. [2007.11]
Norepinephrine transporter gene variation modulates acute response to D-amphetamine. [2007.06.01]
Evaluation of estradiol administration on the discriminative-stimulus and subject-rated effects of d-amphetamine in healthy pre-menopausal women. [2007.06]
The reinforcing, subject-rated, performance, and cardiovascular effects of d-amphetamine: influence of sensation-seeking status. [2007.06]
Behavioral and Subjective Effects of d-Amphetamine and Modafinil in Healthy Adults. [2007.04]
|